AURXNuo Therapeutics, Inc.

About Nuo Therapeutics, Inc. (AURX)

Nuo Therapeutics, Inc. (AURX) is a Biotechnology company headquartered in Houston, TX, United States whose shares trade over-the-counter on the OTCQB tier.

Nuo Therapeutics, Inc. is a biomedical company that pioneers leading-edge biodynamic therapies for wound care. The Company's flagship product, Aurix is a biodynamic hematogel that harnesses a patient's innate regenerative abilities for the management of a variety of wounds.

Products and services

The company manufactures and markets a medical device called the Aurix System which produces an autologous platelet derived hematogel for the treatment of chronic non-healing wounds such as diabetic foot ulcers, venous ulcers and pressure ulcers. In 2021, the Center for Medicare and Medicaid Services (CMS) issued a National Coverage Determination approving Medicare coverage for blood derived products for chronic non-healing wounds where the product has an FDA indication for wound healing management.

AURX key facts

Ticker symbol

AURX

Market tier

OTCQB

Sector

Healthcare

Industry

Biotechnology

Headquarters

Houston, TX, United States

Country of incorporation

US

Year of incorporation

1998

Employees

8

Estimated market cap

$73.51M (as of Apr 10, 2025)

Shares outstanding

46,819,888

Reporting standard

U.S. Reporting: SEC Reporting

Audit status

Audited

Fiscal year end

12/31

Nuo Therapeutics, Inc. leadership

• David E. Jorden — CEO, CFO
• Peter A. Clausen — CSO, COO
• Kristi Vollman — Administrator

Explore more: Biotechnology stocks · Healthcare sector · OTCQB stocks · OTC stocks starting with A